Cargando…

Bioinformatics: A rational combine approach used for the identification and in-vitro activity evaluation of potent β-Glucuronidase inhibitors

Identification of hotspot drug-receptor interactions through in-silico prediction methods (Pharmacophore mapping, virtual screening, 3DQSAR, etc), is considered as a key approach in drug designing and development process. In the current design study, advanced in-silico based computational techniques...

Descripción completa

Detalles Bibliográficos
Autores principales: Yousuf, Maria, Shaikh, Nimra Naveed, Ul-Haq, Zaheer, Choudhary, M. Iqbal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281186/
https://www.ncbi.nlm.nih.gov/pubmed/30517092
http://dx.doi.org/10.1371/journal.pone.0200502
_version_ 1783378792890236928
author Yousuf, Maria
Shaikh, Nimra Naveed
Ul-Haq, Zaheer
Choudhary, M. Iqbal
author_facet Yousuf, Maria
Shaikh, Nimra Naveed
Ul-Haq, Zaheer
Choudhary, M. Iqbal
author_sort Yousuf, Maria
collection PubMed
description Identification of hotspot drug-receptor interactions through in-silico prediction methods (Pharmacophore mapping, virtual screening, 3DQSAR, etc), is considered as a key approach in drug designing and development process. In the current design study, advanced in-silico based computational techniques were used for the identification of lead-like molecules against the targeted receptor β-glucuronidase. The binding pattern of a potent inhibitor in the ligand-receptor X-ray co-crystallize complex was used to identify and extract the structure-base Pharmacophore features. Based on these observations; five structure-based pharmacophore models were derived to conduct the virtual screening of ICCBS in-house data-base. Top-ranked identified Hits (33 compounds) were selected to subject for in-vitro biological activity evaluation against β-glucuronidase enzyme; out of them, twenty compounds (61% of screened compounds) evaluated as actives, however eleven compounds were found to have significantly higher inhibitory activity, including compounds 1, 5–8, 10, 12–13, and 17–19 with IC(50) values ranging from 1.2 μM to 34.9 μM. Out of the eleven potent inhibitors, seven compounds 1, 5, 6, 7, 8, 13, and 19 were found new, and evaluated first time for the β-glucuronidase inhibitory activity. Compounds 1, 5 and 19 exhibited a highly potent inhibition in uM of β-glucuronidase enzyme with non-cytotoxic behavior against the mouse fibroblast (3T3) cell line. Our combined in-silico and in-vitro results revealed that the binding pattern analysis of the eleven potent inhibitors, showed almost similar non-covalent interactions, as observed in case of our validated pharmacophore model. The obtained results thus demonstrated that the virtual screening minimizes false positives, and provide a template for the identification and development of new and more potent β-glucuronidase inhibitors with non-toxic effects.
format Online
Article
Text
id pubmed-6281186
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-62811862018-12-20 Bioinformatics: A rational combine approach used for the identification and in-vitro activity evaluation of potent β-Glucuronidase inhibitors Yousuf, Maria Shaikh, Nimra Naveed Ul-Haq, Zaheer Choudhary, M. Iqbal PLoS One Research Article Identification of hotspot drug-receptor interactions through in-silico prediction methods (Pharmacophore mapping, virtual screening, 3DQSAR, etc), is considered as a key approach in drug designing and development process. In the current design study, advanced in-silico based computational techniques were used for the identification of lead-like molecules against the targeted receptor β-glucuronidase. The binding pattern of a potent inhibitor in the ligand-receptor X-ray co-crystallize complex was used to identify and extract the structure-base Pharmacophore features. Based on these observations; five structure-based pharmacophore models were derived to conduct the virtual screening of ICCBS in-house data-base. Top-ranked identified Hits (33 compounds) were selected to subject for in-vitro biological activity evaluation against β-glucuronidase enzyme; out of them, twenty compounds (61% of screened compounds) evaluated as actives, however eleven compounds were found to have significantly higher inhibitory activity, including compounds 1, 5–8, 10, 12–13, and 17–19 with IC(50) values ranging from 1.2 μM to 34.9 μM. Out of the eleven potent inhibitors, seven compounds 1, 5, 6, 7, 8, 13, and 19 were found new, and evaluated first time for the β-glucuronidase inhibitory activity. Compounds 1, 5 and 19 exhibited a highly potent inhibition in uM of β-glucuronidase enzyme with non-cytotoxic behavior against the mouse fibroblast (3T3) cell line. Our combined in-silico and in-vitro results revealed that the binding pattern analysis of the eleven potent inhibitors, showed almost similar non-covalent interactions, as observed in case of our validated pharmacophore model. The obtained results thus demonstrated that the virtual screening minimizes false positives, and provide a template for the identification and development of new and more potent β-glucuronidase inhibitors with non-toxic effects. Public Library of Science 2018-12-05 /pmc/articles/PMC6281186/ /pubmed/30517092 http://dx.doi.org/10.1371/journal.pone.0200502 Text en © 2018 Yousuf et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Yousuf, Maria
Shaikh, Nimra Naveed
Ul-Haq, Zaheer
Choudhary, M. Iqbal
Bioinformatics: A rational combine approach used for the identification and in-vitro activity evaluation of potent β-Glucuronidase inhibitors
title Bioinformatics: A rational combine approach used for the identification and in-vitro activity evaluation of potent β-Glucuronidase inhibitors
title_full Bioinformatics: A rational combine approach used for the identification and in-vitro activity evaluation of potent β-Glucuronidase inhibitors
title_fullStr Bioinformatics: A rational combine approach used for the identification and in-vitro activity evaluation of potent β-Glucuronidase inhibitors
title_full_unstemmed Bioinformatics: A rational combine approach used for the identification and in-vitro activity evaluation of potent β-Glucuronidase inhibitors
title_short Bioinformatics: A rational combine approach used for the identification and in-vitro activity evaluation of potent β-Glucuronidase inhibitors
title_sort bioinformatics: a rational combine approach used for the identification and in-vitro activity evaluation of potent β-glucuronidase inhibitors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281186/
https://www.ncbi.nlm.nih.gov/pubmed/30517092
http://dx.doi.org/10.1371/journal.pone.0200502
work_keys_str_mv AT yousufmaria bioinformaticsarationalcombineapproachusedfortheidentificationandinvitroactivityevaluationofpotentbglucuronidaseinhibitors
AT shaikhnimranaveed bioinformaticsarationalcombineapproachusedfortheidentificationandinvitroactivityevaluationofpotentbglucuronidaseinhibitors
AT ulhaqzaheer bioinformaticsarationalcombineapproachusedfortheidentificationandinvitroactivityevaluationofpotentbglucuronidaseinhibitors
AT choudharymiqbal bioinformaticsarationalcombineapproachusedfortheidentificationandinvitroactivityevaluationofpotentbglucuronidaseinhibitors